Study inclusion criteria are primarily limited to women aged 50 and older with stage I (≤2 cm), estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+), HER2/neu negative, Luminal A subtype, grade I or II invasive ductal carcinoma. The gene discussed is ERBB2; the disease is invasive ductal breast carcinoma.